Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Saphnelo

Chemical Nameanifrolumab-fnia
Dosage FormInjection (intravenous; 150 mg/mL)
Drug ClassReceptor antagonists
SystemImmune
CompanyAstraZeneca
Approval Year2021

Indication

  • For the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Saphnelo (anifrolumab-fnia) Prescribing Information.2021AstraZeneca Pharmaceuticals LP, Wilmington, DE
Document TitleYearSource
Assessment report: Saphnelo. 2022EMA
Document TitleYearSource
Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials. 2021Zeitschrift für Rheumatologie
Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials.2020Lupus
Additional improvements in clinical response from adjuvant biologic response modifiers in adults with moderate to severe systemic lupus erythematosus despite immunosuppressive agents: A systematic review and meta-analysis.2017Clinical Therapeutics